Equities
  • Price (USD)169.47
  • Today's Change2.45 / 1.47%
  • Shares traded6.98k
  • 1 Year change-49.33%
  • Beta--
Data delayed at least 15 minutes, as of Dec 01 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

  • Revenue in USD (TTM)19.53bn
  • Net income in USD10.86bn
  • Incorporated2008
  • Employees3.08k
  • Location
    BioNTech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
  • Phone+49 49 613190840
  • Fax+49 61 319084390
  • Websitehttps://biontech.de/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
22UA:GER since
announced
Transaction
value
Novartis Singapore Pharmaceutical Manufacturing Pte Ltd-Gpm Manufacturing SiteAnnounced14 Nov 202214 Nov 2022Announced8.30%--
Data delayed at least 15 minutes, as of Dec 02 2022 14:02 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Seagen Inc1.86bn-636.77m22.47bn2.68k--7.94--12.05-3.46-3.4610.1415.230.49081.424.27696,864.70-16.76-5.22-20.63-6.0079.1687.67-34.16-9.783.30-142.610.00---27.6330.36-209.91--13.46--
Horizon Therapeutics PLC3.70bn574.26m22.86bn2.10k41.484.5823.756.182.432.4315.6822.010.41984.315.211,958,455.006.513.937.214.6475.1271.3715.5110.983.749.490.33760.0046.6326.8837.12--37.25--
Alnylam Pharmaceuticals, Inc.960.92m-1.18bn27.10bn1.67k------28.20-9.77-9.777.95-0.54990.27431.456.86577,127.90-33.74-32.56-42.04-37.9483.85---123.02-223.643.33-2.761.07--71.3178.070.6358--3.42--
Gartner Inc5.28bn760.34m28.15bn16.60k38.42--29.475.339.279.2764.37-0.82010.7807--5.11317,918.8011.254.1220.197.0669.3465.0014.416.65--15.861.03--15.4814.13197.5032.603.71--
DuPont de Nemours Inc14.18bn1.16bn34.98bn28.00k30.771.4014.042.472.293.6327.8450.150.31483.545.49506,571.402.71-0.22273.11-0.289235.0531.608.62-1.611.995.110.3173--16.15-19.13172.14-15.09-25.20-26.30
Iqvia Holdings Inc14.31bn1.18bn40.96bn83.00k35.897.6618.392.866.156.1574.4328.780.593--5.76181,101.304.941.776.252.1434.7234.308.343.64--5.190.69860.0022.1415.28246.2468.0831.30--
BioNTech SE - ADR19.53bn10.86bn41.13bn3.08k3.952.133.742.1142.9442.9476.7379.681.019.872.076,338,052.0055.96--73.64--81.71--55.60--5.30--0.0147--3,834.42--67,622.73------
Data as of Dec 01 2022. Currency figures normalised to BioNTech SE's reporting currency: US Dollar USD

Institutional shareholders

11.09%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Sep 20227.25m2.98%
Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 20224.38m1.80%
PRIMECAP Management Co.as of 30 Sep 20224.19m1.73%
Flossbach von Storch AGas of 30 Sep 20223.36m1.38%
Artisan Partners LPas of 30 Sep 20222.23m0.92%
Capital Research & Management Co. (World Investors)as of 30 Sep 20221.62m0.67%
BlackRock Fund Advisorsas of 30 Sep 20221.47m0.61%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20221.26m0.52%
DWS Investment GmbHas of 30 Sep 2022605.63k0.25%
Pictet Asset Management SAas of 30 Sep 2022585.13k0.24%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.